Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant radiotherapy and capecitabine with or without panitumumab in advanced KRAS wild-type rectal cancer
2008-006012-38Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of panitumumab in rectal adenocarcinoma (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Pathological near complete or complete response. Started Oct 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2008-006012-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006012-38.